Prophylaxis and therapy of an experimental XXXX with biological response modifiers.

@entity14018 @entity5 @entity19 @entity7305 @entity150 @entity10165
We have previously reported that the intraperitoneal injection of viable bacillus Calmette-Guerin (BCG) reduces the incidence of @entity5 takes and the rate of @entity5 growth and also increases @entity5 regression rate and survival in C3H/HeN @entity19 challenged with the @entity150 . We have now investigated the immunoprophylactic effect of BCG and other biological response modifiers. Groups of 12 to 15 female C3H/HeN @entity19 were challenged with 5 X 10(5) MBT-2 viable cells and treated with BCG, @entity14018 , @entity10165 , @entity7305 or a combination of these agents. Appropriate controls were included in each experiment. In this study we confirmed previous findings that BCG alone is effective in prophylaxis and can also decrease the rate of @entity5 growth in those animals not protected against @entity5 takes. Both i.p. levamisole and oral @entity10165 lacked activity against the @entity5 . A single i.p. injection of poly I:C was also ineffective although its repeated administration reduced the rate of @entity5 growth and induced a significant number of @entity5 regressions. Combined therapy of BCG with either levamisole or @entity10165 offered no therapeutic advantage over BCG alone. Heat-inactivated BCG also failed to induce anti- @entity5 activity in C3H/HeN @entity19 challenged with MBT-2 cells. These results indicate that live BCG remains the most active immunoprophylactic and immunotherapeutic agent against the MBT-2 @entity19 @entity150 . Furthermore, the anti- @entity5 effect of viable BCG is not potentiated further by the addition of other immune modulating agents.
